Comparison of the effects of photodynamic exposure with the use of chlorine E6 on glioblastoma cells of the U251 line and human embryonic kidney cells of the HEK293 line in vitro
DOI:
https://doi.org/10.25305/unj.306363Keywords:
laser irradiation, photosensitizer, malignant gliomas, glioblastoma, U251, HEK293, mitotic indexAbstract
Malignant gliomas of the brain are a global medical and social problem with a trend toward a steady increase in morbidity and mortality rates. A method that enables the visual identification of tumor tissue and simultaneously selectively destroys it is photodynamic therapy, which involves the introduction of a photosensitizer (PS) followed by its activation at a certain wavelength of light. The selectivity of the accumulation of PS in the tumor tissue of the malignant gliomas is one of the key issues in the problem of increasing the effectiveness of photodynamic therapy.
Objective: to compare the effects of photodynamic exposure using PS chlorin E6 on human glioblastoma (GB) cells of the U251 line and non-malignant human embryonic kidney cells of the HEK293 line.
Material and methods. Groups of cell cultures were formed depending on the conditions of cultivation and exogenous influence: 1) control - cultivated in a standard nutrient medium (Modified Eagle's Medium (MEM)) with L-glutamine, 1 mmol of sodium pyruvate, 10% fetal bovine serum) and experimental: 2) cultivated under the conditions of adding chlorin E6 (concentrations 1.0 and 2.0 μg/ml); 3) cultivated on a nutrient medium without the addition of PS and exposed to laser irradiation (LI) (λ=660 nm, power in the range 0.4-0.6 W, dose in the range 10-75 J/cm2, continuous or pulse mode); 4) cultured under conditions of chlorin E6 addition and subsequent exposure to LI (power in the range 0.4-0.6 W, dose in the range 10-75 J/cm2, continuous or pulse mode). After exposure to the specified experimental factors, dynamic observation with microphotographic registration was performed for 24 h, followed by microscopic and micrometric studies (number of viable cells, total number of cells, mitotic index (MI,%)).
Results. PS chlorin E6 is incorporated into the cytoplasm of cells of U251 and HEK293 cell lines, the intensity of fluorescence is comparable. Upon exposure to chlorin E6 (1.0 and 2.0 μg/ml), cytodestructive and antimitotic effects are increased in a dose-dependent manner in the culture of human GB cells of the U251 line. The cytodestructive effect of chlorin E6 on cell cultures of the HEK293 line is less pronounced, but the antimitotic effect is comparable in both types of cell cultures. Under the influence of LI, cytodestructive and antimitotic effects increase in a dose-dependent manner in the culture of human GB cells of the U251 line. The level of cytodestructive and antimitotic effects is significantly lower in the cultures of non-neoplastic HEK293 cells. The most significant drop in the mitotic activity of GB U251 cells (~100%) was recorded at the lowest LI dose of 25 J/cm2, power of 0.6 W in pulse mode. For HEK293 cells, the most significant decrease in mitotic activity (~80%) was recorded at LI with a power of 0.6 W and dose of 75 J/cm2 in continuous mode. Under the combined effect of chlorin E6 (1 and 2 μg/ml, pre-incubation of 4 h) and LI in different modes, the viability of tumor cells in U251 culture decreases in a dose-dependent manner; the smallest dose of LI to achieve the maximum cytotoxic effect is 25 J/cm2, with a power of 0.6 W in pulse mode when using chlorin E6 at a concentration of 2 μg/ml. The specified characteristics of photodynamic exposure do not cause irreversible effects in HEK293 cultures (reference cells).
Conclusions. An effective mode of photodynamic exposure to achieve a cytodestructive and antimitotic effect in the culture of human GB cells of the U251 line, which is relatively safe for non-malignant cells, has been established: the combined application of a laser irradiation dose of 25 J/cm2, with a power of 0.6 W in pulse mode during the preliminary incubation of the cell culture with chlorin E6 at a concentration of 2 μg/ml for 4 h.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. [CrossRef] [PubMed]
2. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023 Oct 4;25(12 Suppl 2):iv1-iv99. [CrossRef] [PubMed] [PubMed Central]
3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. [CrossRef] [PubMed] [PubMed Central]
4. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. [CrossRef] [PubMed] [PubMed Central]
5. Fedorenko Z, Goulak L, Gorokh Y, Ryzhov A, Soumkina O. CANCER IN UKRAINE, 2021-2022: Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine. 2023;24. http://ncru.inf.ua/publications/BULL_24/PDF_E/bull_eng_24.pdf
6. van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. Advances in local therapy for glioblastoma - taking the fight to the tumour. Nat Rev Neurol. 2022 Apr;18(4):221-236. [CrossRef] [PubMed] [PubMed Central]
7. Mahmoudi K, Garvey KL, Bouras A, Cramer G, Stepp H, Jesu Raj JG, Bozec D, Busch TM, Hadjipanayis CG. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol. 2019 Feb;141(3):595-607. [CrossRef] [PubMed] [PubMed Central]
8. Muller PJ, Wilson BC. Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg. 1996 Oct;14(5):263-70. [CrossRef] [PubMed]
9. Cramer SW, Chen CC. Photodynamic Therapy for the Treatment of Glioblastoma. Front Surg. 2020 Jan 21;6:81. [CrossRef] [PubMed] [PubMed Central]
10. Muragaki Y, Akimoto J, Maruyama T, Iseki H, Ikuta S, Nitta M, Maebayashi K, Saito T, Okada Y, Kaneko S, Matsumura A, Kuroiwa T, Karasawa K, Nakazato Y, Kayama T. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg. 2013 Oct;119(4):845-52. [CrossRef] [PubMed]
11. Quirk BJ, Brandal G, Donlon S, Vera JC, Mang TS, Foy AB, Lew SM, Girotti AW, Jogal S, LaViolette PS, Connelly JM, Whelan HT. Photodynamic therapy (PDT) for malignant brain tumors--where do we stand? Photodiagnosis Photodyn Ther. 2015 Sep;12(3):530-44. [CrossRef] [PubMed]
12. Senders JT, Muskens IS, Schnoor R, Karhade AV, Cote DJ, Smith TR, Broekman ML. Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results. Acta Neurochir (Wien). 2017 Jan;159(1):151-167. [CrossRef] [PubMed] [PubMed Central]
13. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 May;7(5):392-401. [CrossRef] [PubMed]
14. Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B. 1996 Nov;36(2):157-68. [CrossRef] [PubMed]
15. Kaneko S, Fujimoto S, Yamaguchi H, Yamauchi T, Yoshimoto T, Tokuda K. Photodynamic Therapy of Malignant Gliomas. Prog Neurol Surg. 2018;32:1-13. [CrossRef] [PubMed]
16. Schipmann S, Müther M, Stögbauer L, Zimmer S, Brokinkel B, Holling M, Grauer O, Suero Molina E, Warneke N, Stummer W. Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. J Neurosurg. 2020 Jan 24;134(2):426-436. [CrossRef] [PubMed]
17. Vermandel M, Dupont C, Lecomte F, Leroy HA, Tuleasca C, Mordon S, Hadjipanayis CG, Reyns N. Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. J Neurooncol. 2021 May;152(3):501-514. [CrossRef] [PubMed]
18. Eljamel MS, Goodman C, Moseley H. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci. 2008 Oct;23(4):361-7. [CrossRef] [PubMed]
19. van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol. 2017 Oct;135(1):183-192. [CrossRef] [PubMed] [PubMed Central]
20. Lietke S, Schmutzer M, Schwartz C, Weller J, Siller S, Aumiller M, Heckl C, Forbrig R, Niyazi M, Egensperger R, Stepp H, Sroka R, Tonn JC, Rühm A, Thon N. Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences. Cancers (Basel). 2021 Apr 7;13(8):1767. [CrossRef] [PubMed] [PubMed Central]
21. Kobayashi T, Nitta M, Shimizu K, Saito T, Tsuzuki S, Fukui A, Koriyama S, Kuwano A, Komori T, Masui K, Maehara T, Kawamata T, Muragaki Y. Therapeutic Options for Recurrent Glioblastoma-Efficacy of Talaporfin Sodium Mediated Photodynamic Therapy. Pharmaceutics. 2022 Feb 2;14(2):353. [CrossRef] [PubMed] [PubMed Central]
22. Muller PJ, Wilson BC. Photodynamic therapy of brain tumors--a work in progress. Lasers Surg Med. 2006 Jun;38(5):384-9. [CrossRef] [PubMed]
23. Zavadskaya ТS. Photodynamic therapy in the treatment of glioma. Exp Oncol. 2015 Dec;37(4):234-41. [PubMed]
24. Hamaliya MF, Shyshko YD, Shtonʹ IO, Kholin VV, Shcherbakov OB, Usatenko OV. [Photodynamic activity of second-generation photosensitizer fotolon (chlorin e6) and its golden nanocomposite: experiments in vitro and in vivo]. Photobiology and Photomedicine. 2012;9(1-2):99-103. Ukrainian. https://periodicals.karazin.ua/photomedicine/article/view/13195
25. U-251 MG (formerly known as U-373 MG) (ECACC 09063001). Culture Collections. UK Health Security Agency; 2024. https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=09063001&collection=ecacc_gc
26. HEK293 (ECACC 85120602). Culture Collections. UK Health Security Agency; 2024. https://www.culturecollections.org.uk/nop/product/293
27. Lin YC, Boone M, Meuris L, Lemmens I, Van Roy N, Soete A, Reumers J, Moisse M, Plaisance S, Drmanac R, Chen J, Speleman F, Lambrechts D, Van de Peer Y, Tavernier J, Callewaert N. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun. 2014 Sep 3;5:4767. [CrossRef] [PubMed] [PubMed Central]
28. Stepanenko AA, Dmitrenko VV. HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. Gene. 2015 Sep 15;569(2):182-90. [CrossRef] [PubMed]
29. Velazquez FN, Miretti M, Baumgartner MT, Caputto BL, Tempesti TC, Prucca CG. Effectiveness of ZnPc and of an amine derivative to inactivate Glioblastoma cells by Photodynamic Therapy: an in vitro comparative study. Sci Rep. 2019 Feb 28;9(1):3010. [CrossRef] [PubMed] [PubMed Central]
30. Rozumenko VD, Liubich LD, Staino L.P., Egorova D.M., Vaslovych VV, Rozumenko AV, Komarova OS, Dashchakovskyi AV, Kluchka VM, Malysheva TА. Effects of photodynamic exposure using chlorine E6 on U251 glioblastoma cell line in vitro. Ukrainian Neurosurgical Journal. 2023; 29(2): 11-21. [CrossRef]
31. Márquez J, Alonso FJ, Matés JM, Segura JA, Martín-Rufián M, Campos-Sandoval JA. Glutamine Addiction In Gliomas. Neurochem Res. 2017 Jun;42(6):1735-1746. [CrossRef] [PubMed]
32. Rivera JF , Sridharan SV , Nolan JK , Miloro SA , Alam MA , Rickus JL , Janes DB . Real-time characterization of uptake kinetics of glioblastoma vs. astrocytes in 2D cell culture using microelectrode array. Analyst. 2018 Oct 8;143(20):4954-4966. [CrossRef] [PubMed]
33. Moan J, Peng Q. An outline of the history of PDT. Patrice T, editor. Photodynamic Therapy. London: The Royal Society of Chemistry; 2003. p. 1–18. [CrossRef]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Volodymyr D. Rozumenko, Larysa D. Liubich, Larysa P. Staino, Diana M. Egorova, Andrii V. Dashchakovskyi, Victoriya V. Vaslovych, Tatyana А. Malysheva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.